Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

NIV-NAVA in Infants With Severe Bronchiolitis, a Pilot Multicenter Randomized Controlled Trial (NAVIGATE)

16 september 2026 uppdaterad av: Dr Guillaume Emeriaud, St. Justine's Hospital

Non-invasive Ventilation With NAVA in Infants With Severe Bronchiolitis. A Multicenter Pilot Open Label Pragmatic Randomized Controlled Trial (NAVIGATE Trial)

Severe bronchiolitis is a common lung infection in babies that can cause serious breathing problems and often leads to hospitalization in pediatric intensive care units (PICUs). Many infants need special breathing support, usually through non-invasive methods like high-flow oxygen or continuous airway pressure. However, these methods don't always work, and about one in four infants end up needing a breathing tube (intubation), which comes with more risks and a longer recovery.

A newer breathing support method called NIV-NAVA (non-invasive ventilation with neurally adjusted ventilatory assist) may help. It uses signals from the baby's diaphragm to adjust the support in real-time, making breathing easier and possibly reducing the need for intubation. While early results are promising, no high-quality clinical trial has yet tested if NIV-NAVA is better than standard non-invasive support.

This study is a pilot trial - a small-scale version of a larger future study - happening in four PICUs across Canada. It will include 90 babies under 2 years old with severe bronchiolitis who need more support than standard methods provide. Half will receive NIV-NAVA, and half will receive the usual care.

The main goal of this pilot is to check if a larger trial is doable: Can we recruit enough babies? Can the PICU teams stick to the treatment plan? Can we collect the right information? The full study will eventually look at whether NIV-NAVA really lowers the number of babies who need intubation and improves recovery.

This research is led by a team of pediatric experts and could pave the way for better care for thousands of infants with severe breathing problems.

Studieöversikt

Status

Har inte rekryterat ännu

Intervention / Behandling

Detaljerad beskrivning

Goal(s) / Research Aims The primary objective of this multicenter pilot RCT is to determine the feasibility of a definitive multicenter RCT that will evaluate whether NIV-NAVA is superior to conventional NIV in infants with severe bronchiolitis who are not adequately supported by HFNC or CPAP. The primary hypothesis is that the pilot RCT will confirm the feasibility of the final trial.

Methods / Approaches This is an investigator-led, multicenter, randomized, controlled, open-label, pragmatic pilot trial conducted in four Canadian pediatric intensive care units (PICUs) with varying levels of experience with NIV-NAVA, supported by the Canadian Critical Care Trials Group (CCCTG).

Ninety infants younger than 2 years old who are admitted to the PICU with a clinical diagnosis of bronchiolitis, who require NIV support greater than CPAP/HFNC, and who have no exclusion criteria will be randomized 1:1 between NIV-NAVA and conventional NIV management.

The pilot trial's feasibility outcomes are the recruitment rate (the primary outcome), adherence to the intervention, and completion of the definitive trial's outcome measures. The primary outcome of the future definitive RCT is the intubation rate. Secondary outcomes will include respiratory distress evolution, comfort, duration of ventilatory support, PICU and hospital length of stay, nutrition and sedation, complication rates, post-PICU functional outcomes, carbon footprint, and cost-effectiveness analysis.

Expertise. An experienced, multidisciplinary team of senior, mid, and early career clinician scientists with unique expertise in pediatric NIV, trial methodology, pediatric respirology, and PICU research is leading this project.

Expected Outcomes. We expect this pilot trial to confirm the feasibility of a definitive trial on NIV-NAVA in severe bronchiolitis. As the first RCT in this understudied field, it will provide much-needed evidence on the most effective strategy for reducing intubation rates in infants with severe bronchiolitis.

Studietyp

Interventionell

Inskrivning (Beräknad)

90

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Alberta
      • Calgary, Alberta, Kanada
        • Alberta Children's Hospital
        • Kontakt:
    • Ontario
      • Ottawa, Ontario, Kanada
    • Quebec

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

Inte äldre än 2 år (Barn)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Infants younger than 2 years old
  • admitted to the PICU (or managed by the PICU team while awaiting PICU admission)
  • with a clinical diagnosis of bronchiolitis according to the treating team
  • requiring NIV support higher than CPAP/HFNC according to the treating team, a criteria present for less than 8 hours.

Exclusion Criteria:

  • imminent intubation criteria
  • refusal by the physician in charge
  • chronic home ventilation
  • hemodynamic instability requiring vasopressors
  • contraindication to NIV or to gastric tube insertion
  • patients in whom a limitation of life-support treatment is considered

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: NIV-NAVA arm

Installation of an Edi catheter. Ventilation with NIV-NAVA as long as a bi-level NIV support is needed.

Non-invasive support using NAVA technology

Inget ingripande: Control arm (usual care)

Ventilation according to the clinical team. No NAVA ventilation allowed.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Recruitment rate
Tidsram: from initiation to the end of the 6-month study enrolment period

% of eligible patients (identified by screening) who are included in the study at each site and overall

from initiation to the end of the 6-month study enrolment period

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
adherence to the intervention
Tidsram: during the NIV support period, starting from randomization to the end of the bi-level support NIV (=no NIV-NAVA or BIPAP for at least 48 hours), up to a maximum of 28 days

In the NAVA arm : % of patients who receive at least 2 hours of NIV-NAVA support, within 2 hours after randomization. In control arm: absence of NAVA use

during the NIV support period, starting from randomization to the end of the bi-level support NIV (=no NIV-NAVA or BIPAP for at least 48 hours), up to a maximum of 28 days
completion of the definitive trial outcomes
Tidsram: from initiation to the end of the 6-month study enrolment period

completion of the definitive trial outcomes : measurement of intubation rate, duration of ventilatory support, length of PICU and hospital stays

from initiation to the end of the 6-month study enrolment period
Evolution of the respiratory distress mWCAS score
Tidsram: at randomization, and after 2, 6, and 24 hours

Evolution of mWCAS

at randomization, and after 2, 6, and 24 hours
Evolution of the respiratory distress ROX-HR score
Tidsram: at randomization, and after 2, 6, and 24 hours

Evolution of ROX-HR scores

at randomization, and after 2, 6, and 24 hours
Evolution of the comfort score
Tidsram: at randomization, and after 2, 6, and 24 hours

Evolution of the comfort score (FLACC)

at randomization, and after 2, 6, and 24 hours
Capacity to assess the evolution at 3 months post PICU
Tidsram: 3 months post PICU discharge

Percentage of patients with assessment of PICS-p at 3 months post discharge

3 months post PICU discharge

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Guillaume Emeriaud, MD PhD, CHU Sainte Justine, Université de Montréal

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 oktober 2026

Primärt slutförande (Beräknad)

1 maj 2027

Avslutad studie (Beräknad)

1 augusti 2027

Studieregistreringsdatum

Först inskickad

11 september 2026

Först inskickad som uppfyllde QC-kriterierna

16 september 2026

Första postat (Faktisk)

22 september 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

22 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • MP-21-2027-10447
  • 583747 (Annat bidrag/finansieringsnummer: CIHR)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

IPD-planbeskrivning

This is a pilot study. If the pilot shows feasibility of a larger trial with no change in the protocol, we may continue the trial with the same protocol and enroll the subjects from the pilot within the larger trial (Vanguard).

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera